TG 4040
Alternative Names: HCV therapeutic vaccine - Transgene; Hepatitis C vaccine - Transgene; MVA-HCV; TG4040Latest Information Update: 06 Aug 2015
At a glance
- Originator Transgene
- Class Viral hepatitis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 28 May 2013 Intercell has merged with Vivalis to form Valneva
- 29 Apr 2013 Efficacy, adverse events and immunogenicity data from the phase II HCVac trial in Hepatitis C presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013) ,
- 01 Apr 2013 Transgene completes a phase II trial in Hepatitis C in Germany, France, Poland, Spain, USA and Israel (NCT01055821)